MediWound Ltd.
NASDAQ:MDWDBiotechnology
-$0.09 today
- Market cap
- $175.71M
- Beta
- 0.15
- P/E (TTM)
- -7.0
- EPS (TTM)
- -$2.03
Volume 0.17M
Average 0.09M
MDWD Stock-Based Compensation
Employee pay granted in shares or options; a non-cash expense that dilutes existing shareholders.
MediWound Ltd.NASDAQ: MDWD
Stock-Based Compensation · Q1 FY2026 · quarter ended Mar 2026
Stock-based compensation declines year over year
Q1 FY2026 stock-based compensation of $644K fell 23.7% year over year, behind the -16.2% change in trailing-twelve-month stock-based compensation. Sequentially, it fell 2.7% from the prior quarter. Over 3 fiscal years it compounded at +16.9% a year.
Context
- Stock-based compensation amounted to 18.3% of revenue in FY2025, up 2.8 pp from a year earlier.
- Stock-based compensation increased in 1 of the last 3 fiscal years.
What to watch
Whether quarterly growth recovers from -23.7% toward the trailing-twelve-month pace of -16.2%.
Sources:Cash FlowText generated from reported figures; not investment advice.
Stock-Based Compensation history
USD · from the cash flow
- Latest · FY2025
- 3.11M USD
- Year-over-year change
- -1.0%
- 4-year CAGR
- +16.7%
| Period | Period end | Stock-Based Compensation | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 3.11M | -1.0% |
| FY2024 | 2024-12-31 | 3.14M | +61.8% |
| FY2023 | 2023-12-31 | 1.94M | -0.3% |
| FY2022 | 2022-12-31 | 1.95M | +16.3% |
| FY2021 | 2021-12-31 | 1.67M | — |
Stock-Based Compensation vs competitors
How MDWD compares with its peers on the latest reported figures
- Peers report in different currencies, so stock-based compensation is compared through growth and share of revenue rather than absolute size.
- Its year-over-year change of -16.2% is the 7th highest of 9, against a peer median of +26.5%.
- Stock-based compensation amounts to 20.1% of revenue for MDWD, versus a peer median of 312.1%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| FY2025 | €26.77M EUR | +647.7% | +129.4% | 597.1% | |
| LTM Mar 2026 | $15.21M USD | — | — | — | |
| LTM Mar 2026 | $11.86M USD | +7.9% | +52.0% | 36.3% | |
| LTM Mar 2026 | $11.51M USD | -33.2% | -18.7% | 20.6% | |
| LTM Mar 2026 | $10.44M USD | +36.3% | -2.0% | 587.9% | |
| LTM Mar 2026 | $4.36M USD | +16.7% | -17.0% | — | |
| LTM Sep 2026 | $4.19M USD | +122.7% | +4.3% | — | |
| LTM Mar 2026 | $2.91M USD | -16.2% | +16.9% | 20.1% | |
| LTM Mar 2026 | $2.64M USD | +336.0% | +112.4% | — | |
EPRXEupraxia Pharmaceuticals Inc. | LTM Mar 2026 | $1.44M USD | -63.8% | — | — |
| Peer median (excluding MDWD) | — | +26.5% | +4.3% | 312.1% | |
Competitors are the stored peer set for MDWD. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (13.55M) | (19.6M) | (6.72M) | (30.22M) | (23.88M) |
| Depreciation & Amortization | 1.24M | 1.27M | 1.3M | 1.48M | 1.71M |
| Deferred Income Tax | (124K) | 0 | 0 | 0 | 0 |
| Stock-Based Compensation | 1.67M | 1.95M | 1.94M | 3.14M | 3.11M |
| Change in Working Capital | 162K | (7.24M) | 2.34M | 1.27M | 4.77M |
| Accounts Receivables | 929K | (7.58M) | 4.76M | (1.02M) | 4.88M |
| Inventory | 257K | (721K) | (906K) | 187K | (1.36M) |
| Accounts Payables | 1.72M | 414K | (594K) | 406K | 2.35M |
| Other Working Capital | (2.75M) | 645K | (928K) | 1.7M | (1.1M) |
| Other Non-Cash Items | 1.69M | 11.74M | (9.33M) | 10.71M | (236K) |
| Operating Cash Flow | (8.92M) | (11.89M) | (10.47M) | (13.62M) | (14.53M) |
| Capital Expenditures | (489K) | (555K) | (6.46M) | (6.27M) | (5.51M) |
| Acquisitions (Net) | 0 | 0 | 0 | 0 | 0 |
| Purchases of Investments | 0 | 0 | 0 | 0 | (14.04M) |
| Sales of Investments | 4M | 0 | 0 | 0 | 0 |
| Other Investing Activities | 35K | 74K | (27.86M) | (2.12M) | 0 |
| Investing Cash Flow | 3.55M | (481K) | (34.32M) | (8.4M) | (19.54M) |
| Debt Repayment | 0 | 0 | 0 | (928K) | 0 |
| Common Stock Issued | 3K | 38.38M | 24.91M | 22.17M | 31.05M |
| Common Stock Repurchased | 0 | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | (1.05M) | (2.62M) | (1.99M) | (1.84M) | (1.43M) |
| Financing Cash Flow | (1.05M) | 35.76M | 22.92M | 19.39M | 29.62M |
| Effect of Forex Changes | 88K | (549K) | (160K) | (84K) | 95K |
| Net Change in Cash | (6.33M) | 22.85M | (22.03M) | (2.71M) | (4.36M) |
| Free Cash Flow | (9.41M) | (12.44M) | (16.93M) | (19.9M) | (20.04M) |
MediWound Ltd.
NASDAQ:MDWD
Intrinsic Alpha fair value
Locked
Current Price
$13.61
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.